Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02523118 · ClinicalTrials.gov registry record

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

A clinical trial of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis, sponsored by Children's Hospital Medical Center, Cincinnati.

Recruiting
Registry status
1,350
Enrollment target
19
Study locations

NCT02523118: Recruiting study of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis, sponsored by Children's Hospital Medical Center, Cincinnati.

NCT02523118 is a study of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 1,350 participants, above the 833-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (62% higher). The trial reports 19 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02523118, a study of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.

RECRUITING
Registry status
1,350 participants
Enrollment target
19
Study locations

Study Summary

The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We are aiming to compare different tissue components such as inflammatory cell types with clinical symptoms. We want to see if scores on standard questionnaires can give us an idea how well the person is doing.

Primary Outcome

Mucosal eosinophil levels are measured as eosinophils per high power field (eos/hpf). The primary outcome measure is to determine the change in mucosal eosinophil level (eos/hpf) and to determine if the change in mucosal eosinophil level in eos/hpf correlates with the change in scores on clinical outcome measure metrics.

Study Locations (19)

Colorado

  • University of Colorado Denver - Aurora
  • Children's Hospital Colorado - Denver

Illinois

  • Northwestern University - Chicago
  • Ann and Robert H. Lurie Children's Hospital of Chicago - Chicago

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • University of Pennsylvania - Philadelphia

Arizona

  • Mayo Clinic Hospital - Phoenix

Arkansas

  • Arkansas Children's Research Institute - Rogers

California

  • Rady Children's Hospital - San Diego

Indiana

  • Riley Children's Hospital - Indianapolis

Maryland

  • National Institutes of Health (NIH) - Bethesda

Trial Details

FieldValue
Enrollment Target 1,350 participants
Start Date 2015-07-17
Est. Completion 2051-01-01

What NCT02523118 shows while recruiting

NCT02523118 is an observational study that tracks outcomes without assigning an intervention. Its 1,350 participants enrollment target places it among the larger protocols in the corpus, above the 833-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (62% higher).

The record links to 5 conditions, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 0 interventions.

NCT02523118 lists 19 locations in 16 states (Colorado, Illinois, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT02523118 about?

NCT02523118 is a clinical study titled "OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages". The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based ...

What is the current status of trial NCT02523118?

This trial is currently recruiting. The enrollment target is 1,350 participants. The study started on 2015-07-17. Estimated completion is 2051-01-01.

What conditions does trial NCT02523118 study?

This clinical trial studies the following conditions: Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, Eosinophilic Gastritis, Eosinophilic Colitis, Eosinophilic Gastrointestinal Disorders (EGIDs).

Who is sponsoring clinical trial NCT02523118?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02523118 being conducted?

This trial has 19 study locations across Arizona, Arkansas, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eosinophilic Esophagitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02523118's enrollment target sits among peer trials

1,350 5th of 44 higher than 40 of 44 other Eosinophilic Esophagitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06318169 · 1,350 participants · Phase 3

    A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  • NCT06605404 · 1,350 participants

    Pan-tumor MRD Study

  • NCT06806163 · 1,350 participants · NA

    Machine-Learning Prediction and Reducing Overdoses With EHR Nudges

  • NCT06731608 · 1,344 participants · NA

    OsteoPorotic fracTure preventION System (OPTIONS) Research Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02523118, the US trial registry maintained by the National Library of Medicine. NCT02523118 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.